On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

Prevention of osteoporosis should be considered before a bone break occurs, and many patients at risk for the chronic bone condition may benefit from pharmacologic options. "Most current guidelines ...

CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...

The study explores whether denosumab, a widely used therapy for osteoporosis and bone tumors, can regenerate beta cells, which produce insulin City of Hope, one of the largest and most advanced cancer ...

SEATTLE — Treatment with romosozumab improved lumbar spine, total hip, and femoral neck bone mineral density (BMD) in women with premenopausal idiopathic osteoporosis (IOP), according to new results ...

The FDA approved Stoboclo and Osenvelt as interchangeable biosimilars for Prolia and XGEVA, enhancing patient access and reducing costs. These biosimilars treat osteoporosis and bone mass loss in ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we have ...

Breakthrough Research on Osteoporosis Millions of women experience pain and frequent fractures due to weakened bones after ...

Bildyos and Bilprevda are FDA-approved biosimilars to Prolia and Xgeva, expanding access to bone care treatments in the U.S. Bildyos treats osteoporosis and bone loss in cancer therapies, while ...

City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States and a top research center for diabetes and other life-threatening illnesses, is ...